When a patient with moderate-to-severe rheumatoid arthritis fails two conventional disease-modifying antirheumatic drugs (DMARDs), guidelines recommend a biologic therapy within weeks. But in the UK, that recommendation meets a wall of paperwork. Prior authorization — the requirement for clinicians to obtain approval before prescribing certain drugs — adds an average 8–12 week delay for tumour necrosis factor (TNF) inhibitors such as adalimumab. One in five first submissions is denied, and each appeal consumes three to five hours of consultant time. The delays carry clinical consequences. Yet no central registry tracks how often patients fail step-therapy mandates, leaving the system blind to its own inefficiencies.

The problem extends beyond rheumatology. In dermatology, prior authorization for biologics used in psoriasis follows a similar pattern. In gastroenterology, infliximab for inflammatory bowel disease faces comparable hurdles. The common thread is a step-therapy requirement: patients must try and fail a cheaper, older drug before the NHS will cover a more expensive biologic. While step therapy aims to control costs, the lack of data on failure rates means the policy's clinical toll remains unmeasured.

The Prior Authorization Bottleneck for UK Biologics

Prior authorization in the UK operates through a patchwork of local formularies and commissioning policies. Each NHS trust sets its own criteria for biologic approvals, often requiring that patients have failed two or three conventional DMARDs, plus a trial of corticosteroids or other bridging therapy. The process typically involves a consultant completing a lengthy form, submitting lab results and imaging evidence, and waiting for a panel review. According to surveys of rheumatologists, roughly 20% of first submissions are denied, often for missing documentation or borderline disease activity scores.

A 2024 survey of UK rheumatologists found that each prior authorization request consumes roughly 30–45 minutes of consultant time, with appeals adding another two to three hours. For a department managing 50–100 biologic starts per year, that translates to hundreds of hours diverted from direct patient care. Some trusts have tried to streamline the process by using electronic templates, but adoption remains uneven. A consultant in a large teaching hospital might process a request in two weeks; a colleague in a district general hospital might face three months.

The financial logic of step therapy is straightforward: older DMARDs like methotrexate cost pennies per dose, while biologics can run £10,000–£15,000 per patient per year. By mandating a trial of cheaper alternatives, the NHS aims to avoid unnecessary spending on drugs that may not be needed. But the assumption that step therapy saves money rests on the idea that failure rates are low. If 30–40% of patients fail first-line DMARDs within six months, as some studies suggest, then the delays may simply shift costs — from drug budgets to hospitalizations, lost productivity, and disability.

When a denial arrives, the consultant must gather additional evidence — often a repeat disease activity score, a letter from the patient about functional limitations, or a second opinion. One rheumatologist described spending an entire afternoon on a single appeal for a young woman whose joints were deteriorating visibly. London NHS psychiatrist caseloads are also stretched, and the parallel with overburdened specialists is clear: administrative tasks compete with clinical time.

Step-Therapy Failures Are a Blind Spot in Outcomes Data

Despite the prevalence of step-therapy mandates, the UK has no national registry that tracks how often patients fail these requirements. A 2024 study in Rheumatology provided one of the few attempts to quantify failure rates, finding that roughly a third of patients with rheumatoid arthritis did not respond adequately to two conventional DMARDs within six months. But the study relied on data from a single large trust, and the authors noted that failure criteria varied widely — some trusts defined failure as a lack of 20% improvement in disease activity, others as the occurrence of intolerable side effects, and still others as any disease flare that required corticosteroids.

This variability undermines the equity that prior authorization is supposed to protect. If the goal is to ensure that only appropriate patients receive biologics, then the criteria for appropriateness should be consistent. Currently, they are not. A patient who fails step therapy in one trust might be deemed a non-responder in another — or might be kept on a failing regimen for months longer.

NICE (the National Institute for Health and Care Excellence) has acknowledged the evidence gap. In its 2023 guideline update on rheumatoid arthritis, the committee noted that "the optimal duration of a trial of conventional DMARDs before escalation to biologic therapy is uncertain" and called for more research. But no action plan has emerged. Meanwhile, observational data from other countries suggest that delays in biologic initiation are associated with worse radiographic outcomes. A 2020 meta-analysis found that each month of delay increased the risk of joint erosion by roughly 5%, and the effect was most pronounced in patients with high baseline disease activity.

A 45-year-old woman who waits 12 weeks for adalimumab may develop erosions that no later therapy can reverse. Her functional decline may mean she cannot return to her job as a nurse or a teacher. The system counts the cost of the drug but not the cost of the disability. Without a registry that tracks step-therapy failures, the true price of prior authorization remains hidden.

What the TRANSCEND Trial Says About Access Delays

The TRANSCEND trial, published in the New England Journal of Medicine in July 2026, tested setmelanotide (Imcivree), a melanocortin-4 receptor agonist, in patients with acquired hypothalamic obesity — a condition that causes severe, refractory weight gain after hypothalamic damage from tumors or surgery. The phase III results showed a 15–20% reduction in body mass index over 12 months, with improvements in hunger scores. For a patient group with few other options, the drug represents a meaningful advance.

But in the UK, setmelanotide requires prior authorization through NHS England's specialized commissioning process. Patients must first have a confirmed diagnosis of hypothalamic obesity, documented failure of lifestyle interventions, and evidence of hyperphagia. The approval process can take three to six months, during which time patients continue to gain weight and develop complications such as type 2 diabetes and sleep apnea. The drug's list price is around £30,000 per year, and while NICE has not yet issued full guidance, early access is limited to a handful of tertiary centres.

The TRANSCEND trial itself did not address access delays, but the authors noted that "timely initiation of therapy is critical to prevent irreversible metabolic sequelae." For rare diseases, the prior authorization burden is often higher because fewer clinicians are familiar with the condition, and the evidence base is thinner. A consultant endocrinologist may need to write a detailed case for funding, including a literature review and letters of support from multiple specialists. The administrative burden falls disproportionately on the few clinicians who treat these patients.

In both rheumatology and rare diseases, the system demands proof of failure before approving a newer therapy, but the definition of failure is narrow and the process slow. For rare diseases, the stakes are even higher because alternative treatments are often nonexistent. The TRANSCEND trial offers a reminder that access delays are not just a rheumatology problem — they affect patients across specialties, and the lack of an expedited pathway for rare diseases compounds the inequity.

Hidden Costs: Administrative Burden and Clinical Deterioration

The administrative burden of prior authorization extends beyond consultants. General practitioners (GPs) often initiate the referral process for biologic therapy, and they spend an estimated two to four hours per case on paperwork, including documenting prior DMARD trials, completing forms, and chasing missing lab results. For a practice that sees several such patients per month, this time adds up quickly. A 2025 survey of 200 UK rheumatologists found that 68% had seen patients who required an emergency department visit or hospitalization while waiting for biologic approval. These events are often preventable — a patient who flares while waiting for adalimumab may need intravenous steroids or even surgery for a septic joint.

The indirect costs are rarely quantified. Patients miss work, require carer support, and experience reduced quality of life during the waiting period. A 2023 study from the University of Manchester estimated that the average patient with rheumatoid arthritis loses roughly 10 working days per year due to flares, and a significant proportion of those flares occur during transitions between therapies. If prior authorization delays add two months to the transition, the lost productivity could amount to hundreds of pounds per patient. Multiplied across thousands of patients, the cost to the economy likely offsets the drug savings from step therapy.

NHS England has piloted an electronic prior authorization system in a few trusts, aiming to reduce turnaround times to under two weeks. The pilot uses a standardized digital form that auto-populates patient data from electronic health records and allows reviewers to approve or deny with a single click. Early results are promising, with approval times dropping to a median of 8 days. But rural Kenyan nurse vacancies highlight how resource constraints can slow implementation; in the UK, rollout has been delayed by IT integration issues and resistance from trusts that prefer their own processes.

Some trusts have tried to reduce the burden by using nurse specialists to manage prior authorization paperwork, freeing consultants for clinical work. But these roles are not uniformly funded, and in many hospitals, the consultant remains the bottleneck. The hidden cost is not just the time spent on forms, but the opportunity cost of that time — the patients who wait longer for appointments, the research projects that stall, the teaching that gets postponed.

Comparison to US and EU Prior Authorization Systems

The UK is not alone in requiring prior authorization for biologics, but its approach stands out for its combination of step therapy with local formulary variation. In the United States, prior authorization is pervasive: a 2025 American Medical Association survey found that 92% of physicians reported delays due to prior authorization, and the average physician spends nearly 15 hours per week on these tasks. However, US insurers often have more standardized criteria, and appeals can be expedited through peer-to-peer reviews. The downside is that patients may face different requirements from different insurers, creating confusion and coverage gaps.

In Germany, the system is more streamlined. Biologics for rheumatoid arthritis are approved automatically within 7 days if the prescribing physician documents that the patient meets criteria set by the German Rheumatology Society. Step therapy is rarely enforced; instead, the focus is on appropriate diagnosis and monitoring. A 2024 comparison of UK and German access times found that German patients started biologics roughly 6 weeks sooner on average, with lower rates of disease progression at one year. The German system invests in electronic health records that automatically check eligibility, reducing the administrative burden on clinicians.

France takes a different approach: step therapy is recommended but not mandated for TNF inhibitors. The French health authority (HAS) publishes guidelines that encourage a trial of conventional DMARDs, but clinicians can prescribe biologics at their discretion if they believe the patient is unlikely to respond. In practice, most patients receive a short trial of methotrexate before moving to a biologic, but the process is faster because no formal prior authorization is required. As a result, French patients with moderate-to-severe rheumatoid arthritis typically start biologics within 4–6 weeks of diagnosis, compared to 12–16 weeks in the UK.

The variation across countries suggests that prior authorization is not a technical necessity but a policy choice. The UK's approach reflects a desire to control drug spending in a centralized system, but it may be achieving that goal at the expense of clinical outcomes. No cross-country audit has directly compared step-therapy failure rates, but the evidence from Germany and France implies that faster access does not lead to widespread overuse. Instead, it appears to reduce the burden of disease without increasing overall costs.

What Clinicians Can Do While the System Catches Up

While systemic change is slow, clinicians can take practical steps to mitigate the impact of prior authorization delays. First, document every step-therapy failure with objective measures. A disease activity score, a functional assessment, and a patient-reported outcome measure at baseline and after each DMARD trial create a clear record that can support an appeal. If the criteria for failure are vague, a detailed note can make the case stronger. Second, use shared decision aids to set expectations. Patients who understand that the process may take several months are less likely to become frustrated or abandon treatment.

Third, lobby for a national step-therapy failure registry. Professional organizations such as the British Society for Rheumatology have called for better data collection, but progress has been slow. Clinicians can contribute by reporting failures through existing registries like the British Society for Rheumatology Biologics Register (BSRBR) and by advocating for standardized definitions. The UK postnatal chlamydia screening lapses offer a cautionary tale about gaps in data collection; a similar gap now exists for step-therapy failures.

Fourth, consider bridging therapies during the waiting period. Short courses of corticosteroids or NSAIDs can control flares, though they carry their own risks. For patients with high disease activity, a temporary switch to a different conventional DMARD may buy time. The goal is to prevent irreversible joint damage while the prior authorization process unfolds. Finally, report adverse outcomes via the MHRA yellow card scheme. If a patient develops a serious infection or requires hospitalization while waiting for a biologic, that event should be recorded. Over time, such reports can build a case for policy change.

None of these steps is a substitute for systemic reform. The prior authorization system in the UK needs a unified electronic platform, standardized criteria, and a faster appeals process. But until those changes arrive, clinicians must work within the constraints. The evidence from trials like TRANSCEND and from international comparisons suggests that the current approach is costing patients more than it saves. The question is whether the system will respond to that evidence — or wait for a crisis to force change.

This article is for informational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional.